Olema Pharmaceuticals, Inc.NASDAQ: OLMA

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

· Issued by Olema Pharmaceuticals, Inc. via GlobeNewswire

Summary by 6ix AI

Olema Pharmaceuticals, Inc. (Olema Oncology), a clinical-stage company developing breast cancer treatments, granted stock options to six new employees to buy a total of 235,950 shares of its common stock at $8.27 per share, effective as of October 1, 2026.

Key details

  • The $8.27 exercise price equals the last reported sale price of Olema's common stock on Nasdaq on October 1, 2026, and the options have a 10-year term.
  • The awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options vest over four years: 25 percent on the first anniversary of each employee's vesting start date and the rest in 36 equal monthly installments over the following three years.

What’s still pending

  • Vesting depends on each employee remaining continuously employed by Olema on the vesting dates.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635c4

Olema Oncology

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $8.27 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on October 1, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O'Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]

Olema Pharmaceuticals, Inc. on 6ix

Earlier from Olema Pharmaceuticals

Later from Olema Pharmaceuticals

All Olema Pharmaceuticals news releases